Polykystinen ovary syndrome, now termed polyendocrine metabolic ovarian syndrome (PMOS), is a global condition affecting 170 million women and frequently associated with obesity and insulin resistance. Incretin-based therapies, such as glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/GIP agonists, represent a potential approach to addressing metabolic dysfunction within this population.
Clinical Findings and Therapeutic Approaches
Clinical trial evidence indicates that liraglutide, semaglutide, and tirzepatide produce reductions in body weight, body mass index (BMI), and waist circumference. Some studies have observed preferential effects on visceral and ectopic fat. Glycemic and insulin resistance outcomes demonstrate variability across studies. Lipid and blood pressure effects have not been fully characterized.
Future Research Directions
Available evidence suggests that higher-potency agents may offer more consistent weight-loss benefits. However, current research does not establish comparative metabolic superiority among the agents within the PMOS population. Interpretation of the data is limited by short-term trials at sub-obesity doses, frequent co-administration with metformin, and a lack of phenotype-stratified data. Larger, longer, and higher-dose trials are required to comprehensively define the anthropometric and metabolic potential of these therapies in women with PMOS.